🚀 VC round data is live in beta, check it out!
Hepalink Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hepalink and similar public comparables like Yifan Pharmaceutical, Nippon Shinyaku, PegBio, Natco Pharma and more.
Hepalink Overview
About Hepalink
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
Founded
1998
HQ
Employees
1.9K
Website
Sectors
Financials (LTM)
EV
$2B
Hepalink Financials
Hepalink reported last 12-month revenue of $805M and EBITDA of $127M.
In the same LTM period, Hepalink generated $127M in EBITDA and $65M in net income.
Revenue (LTM)
Hepalink P&L
In the most recent fiscal year, Hepalink reported revenue of $803M and EBITDA of $124M.
Hepalink expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $805M | XXX | $803M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $256M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $127M | XXX | $124M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $65M | XXX | $51M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $106M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hepalink Stock Performance
Hepalink has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Hepalink's stock price is $1.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -2.0% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHepalink Valuation Multiples
Hepalink trades at 2.7x EV/Revenue multiple, and 17.3x EV/EBITDA.
EV / Revenue (LTM)
Hepalink Financial Valuation Multiples
As of April 18, 2026, Hepalink has market cap of $2B and EV of $2B.
Equity research analysts estimate Hepalink's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hepalink has a P/E ratio of 33.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 17.3x | XXX | 17.7x | XXX | XXX | XXX |
| EV/EBIT | 23.5x | XXX | 23.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.6x | XXX | XXX | XXX |
| P/E | 33.5x | XXX | 42.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 9.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hepalink Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hepalink Margins & Growth Rates
Hepalink's revenue in the last 12 month grew by 7%.
Hepalink's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Hepalink's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hepalink's rule of X is 32% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hepalink Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hepalink Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hepalink | XXX | XXX | XXX | XXX | XXX | XXX |
| Yifan Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Nippon Shinyaku | XXX | XXX | XXX | XXX | XXX | XXX |
| PegBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Natco Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eris Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hepalink M&A Activity
Hepalink acquired XXX companies to date.
Last acquisition by Hepalink was on XXXXXXXX, XXXXX. Hepalink acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hepalink
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHepalink Investment Activity
Hepalink invested in XXX companies to date.
Hepalink made its latest investment on XXXXXXXX, XXXXX. Hepalink invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hepalink
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hepalink
| When was Hepalink founded? | Hepalink was founded in 1998. |
| Where is Hepalink headquartered? | Hepalink is headquartered in China. |
| How many employees does Hepalink have? | As of today, Hepalink has over 1K employees. |
| Is Hepalink publicly listed? | Yes, Hepalink is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Hepalink? | Hepalink trades under 002399 ticker. |
| When did Hepalink go public? | Hepalink went public in 2010. |
| Who are competitors of Hepalink? | Hepalink main competitors are Yifan Pharmaceutical, Nippon Shinyaku, PegBio, Natco Pharma. |
| What is the current market cap of Hepalink? | Hepalink's current market cap is $2B. |
| What is the current revenue of Hepalink? | Hepalink's last 12 months revenue is $805M. |
| What is the current revenue growth of Hepalink? | Hepalink revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Hepalink? | Current revenue multiple of Hepalink is 2.7x. |
| Is Hepalink profitable? | Yes, Hepalink is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hepalink? | Hepalink's last 12 months EBITDA is $127M. |
| What is Hepalink's EBITDA margin? | Hepalink's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Hepalink? | Current EBITDA multiple of Hepalink is 17.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.